APLS - Latest News

Apellis Pharmaceuticals, Inc. (APLS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $5.25B. Trailing twelve-month P/E ratio is 38.80. Beta to the broader market is -0.25.

The article list below shows the most recent APLS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent APLS Headlines

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

gurufocus.com - May 31, 2026

[url="]Pfizer Inc.

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

gurufocus.com - May 30, 2026

[url="]Pfizer Inc.

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

prnewswire.com - May 7, 2026

NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics

zacks.com - May 7, 2026

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be wor

Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates

zacks.com - May 7, 2026

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.

How News Affects APLS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track APLS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.